Certara Announces Acquisition of Great Lakes Drug Development, Inc.
Acquisition will further increase the depth of Certara?s early drug development analysis, modeling and simulation expertise
Certara
™, a provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that it has acquired drug development consultancy firm, Great Lakes Drug Development, Inc. (“GLDD”), based in Brighton, MI. Both companies possess considerable expertise in pharmacokinetic (PK) and pharmacodynamic (PD) analysis, project management, and pharmacometric modeling and simulation. GLDD focuses on early development work, while Certara’s products and services span the entire drug development continuum. Financial details about the transaction have not been disclosed.
“This acquisition will enable us to leverage the significant synergies between Certara’s and GLDD’s business focus, experience, and culture, while expanding our customer base,” said Daniel Weiner, Ph.D., senior vice president and general manager at Certara.
The addition of GLDD builds on the capabilities Tripos®, Pharsight® and Simcyp™ bring to Certara.
GLDD’s Chief Executive Officer David Hermann, said, “This is an exciting stage in our company’s evolution. We look forward to joining Certara’s Pharsight Consulting Services to enhance their capabilities and provide our customers with access to additional services and expertise.”
The GLDD office in Brighton, MI will become the sixth in Certara’s worldwide consultancy operations including 75 Ph.D. staff in Sunnyvale, CA; Cary, NC; Montreal, Canada; Tokyo, Japan; and Sheffield, England.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
